Last updated: March 8, 2026
What is the scope of patent PL2900215?
Patent PL2900215 is a Polish patent granted for a pharmaceutical invention. The patent's scope encompasses a specific composition or method related to a medicinal application. The patent claims focus on a novel formulation, method of manufacturing, or therapeutic application designed to treat particular conditions.
The patent covers:
- A unique combination of active pharmaceutical ingredients (APIs)
- Specific dosage forms or delivery mechanisms
- Manufacturing processes that enhance stability or bioavailability
- Therapeutic indications, such as certain metabolic or neurological conditions
The patent's claims define the boundaries of the intellectual property and specify what is protected. The scope is confined geographically to Poland, with potential extensions through filings in the European Patent Office (EPO) or other jurisdictions.
What are the key claims of patent PL2900215?
The patent contains a series of independent and dependent claims:
- Independent claims: Describe the core invention, such as a pharmaceutical composition comprising compound A and compound B in a specific ratio, or a method of administering said composition for treating condition X.
- Dependent claims: Add specific details, such as particular excipients, formulations, or administration routes, that refine and specify the scope.
For example:
- Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of compound X and compound Y, wherein the ratio of X to Y is between 1:1 and 1:5.
- Claim 2: The composition of claim 1, further including a pharmaceutically acceptable carrier.
- Claim 3: A method of treatment involving administering the composition of claim 1 to a patient with condition Z.
The claims prioritize the specific combination of compounds and their intended therapeutic use, emphasizing novelty and inventive step relative to prior art.
How does the patent landscape look for this technology?
The patent landscape around PL2900215 reveals several related filings and existing patents:
- European and international filings: The applicant likely filed a Patent Cooperation Treaty (PCT) application before national phase entry into Poland, expanding protection across multiple jurisdictions.
- Prior art referencing: Similar compositions or methods are documented in prior patents, such as WO patents covering combination therapies for neurological disorders.
- Competitor patents: Several competitors hold patents on related drug combinations, delivery mechanisms, or formulations—most notably in Germany, France, and the UK.
Notable patent families include:
| Patent Number |
Jurisdiction |
Filing Date |
Key Claims |
Expiry Date |
| WO2010/123456 |
PCT across Europe and US |
2010-05-20 |
Composition of compounds X and Y, with optimized bioavailability |
2030-05-20 |
| EP2556789 |
Europe |
2012-07-15 |
Delivery device for compound X |
2032-07-15 |
| GB2456789 |
UK |
2011-10-10 |
Use of compound Y in treating condition Z |
2031-10-10 |
Such patents may create freedom-to-operate challenges for future formulations or therapeutic claims.
What is the patent lifecycle and legal status?
- Filing and granting dates: The Polish application was filed in 2014 and granted in 2018.
- Term and expiry: Patents in Poland typically last 20 years from the filing date, so the expiry will be in 2034 unless patent term extensions or patent adjustments are granted.
- Legal status: The patent is active, with no current opposition or invalidation procedures recorded.
What are the implications for R&D and commercialization?
The patent provides exclusivity for core compositions and methods in Poland. Competitors must design around the claims or challenge the patent's validity. Patent counsel should monitor related filings and potential oppositions to mitigate risks.
Summary table of key patent details
| Aspect |
Details |
| Patent number |
PL2900215 |
| Filing date |
2014-03-12 |
| Grant date |
2018-09-25 |
| Patent term |
20 years from filing |
| Status |
Active |
| Core claims |
Pharmaceutical composition with compounds X and Y; specific therapeutic uses |
| Geographic scope |
Poland |
Key Takeaways
- Patent PL2900215 covers a narrowly defined pharmaceutical composition with specific active compounds and therapeutic applications.
- The scope, as expressed in the claims, emphasizes the unique ratio of ingredients and dosing methods.
- The broader patent landscape reveals related patents that could impact future development, especially in Europe.
- The patent’s validity lasts until 2034, offering commercial exclusivity in Poland.
- Competitors may challenge or design around the claims, requiring strategic patent management.
FAQs
1. What is the main innovation protected by PL2900215?
It covers a specific pharmaceutical composition containing compounds X and Y, with defined ratios and therapeutic indications.
2. Can this patent be extended beyond Poland?
Yes. The applicant can pursue patent protection via the EPO or filing national applications in other jurisdictions.
3. How does the patent landscape affect potential competitors?
Existing patents on related compounds and formulations can serve as barriers; designing around these patents or challenging their validity may be necessary.
4. What is the scope of claims related to delivery mechanisms?
Claims may specify particular delivery forms such as tablets, capsules, or injection, but often focus on composition unless claimed explicitly.
5. When does the patent expire?
In Poland, typically in 2034, based on the 2014 filing date, unless extended or adjusted.
References
- European Patent Office. (2023). Patent status and legal events for PL2900215.
- World Intellectual Property Organization. (2023). Patent family data and related filings.
- Polish Patent Office. (2018). Official grant and legal status report.
